Keywords: ph, ii, nsclc, asa404, trial, supports, earlier

Ph II NSCLC ASA404 trial supports earlier findings

Article | 17 September 2007

Print This

UK-based drug developer Antisoma says that data from a study of its anticancer agent ASA404, presented at the World Conference ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in